文献速递胸部肿瘤

非典型B细胞(CD21-CD27-IgD-)与非小细胞肺癌免疫检查点抑制剂治疗无应答相关

Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.
PubMed 文献 · Eur J Cancer · 2023-11-11

本研究采用流式细胞术检测非小细胞肺癌和间皮瘤患者接受检查点抑制剂(CI)治疗前外周血B细胞的存留与表型,并与临床结局关联。结果显示,无应答患者B细胞频率降低,但抗原经历型CD21-双阴性(非典型)B细胞频率较应答患者和健康对照升高,在间皮瘤患者中得到验证。结论认为CD21-双阴性B细胞频率与胸部恶性肿瘤CI治疗无应答相关,其机制尚不明确。

要点

  • 无应答患者B细胞频率降低,而CD21-双阴性(非典型)B细胞频率升高。
  • 该现象在间皮瘤CI治疗患者中得到验证。
  • CD21-双阴性B细胞妨碍CI治疗的机制尚不清楚。

核心结论

  • CD21-双阴性B细胞频率与胸部恶性肿瘤CI治疗无应答相关。
  • CD21-双阴性B细胞妨碍CI治疗的机制尚不明确。
  • 作者认为CD21-双阴性B细胞表型上类似慢性感染中所见的耗竭B细胞,或作为抗原提呈细胞诱导调节性T细胞。

研究设计与样本

  • 研究纳入非小细胞肺癌和间皮瘤患者,在接受CI治疗前采用流式细胞术评估外周血B细胞的存留与表型,并与临床结局关联。

主要发现

  • 无应答患者B细胞频率较应答患者和健康对照降低。
  • 无应答患者抗原经历型CD21-双阴性(非典型)B细胞频率较应答患者和健康对照升高。
  • 上述B细胞频率变化在间皮瘤CI治疗患者中得到验证。

局限性

  • CD21-双阴性B细胞妨碍CI治疗的机制尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Checkpoint inhibitor (CI) therapy has revolutionized treatment for non-small cell lung cancer (NSCLC). However, a proportion of patients do not respond to CI therapy for unknown reasons. Although the current paradigm in anti-tumor immunity evolves around T cells, the presence of tertiary lymphoid structures and memory B cells has been positively correlated with response to CI therapy in NSCLC. In addition, double negative (DN) (CD27- IgD-) B cells have been shown to be abundant in NSCLC compared to healthy lung tissue and inversely correlate with the intratumoral presence of memory B cells. Nonetheless, no study has correlated DN B cells to survival in NSCLC. METHODS: In this study, we evaluated the presence and phenotype of B cells in peripheral blood with flow cytometry of patients with NSCLC and mesothelioma before receiving CI therapy and correlated these with clinical outcome. RESULTS: Non-responding patients showed decreased frequencies of B cells, yet increased frequencies of antigen-experienced CD21- DN (Atypical) B cells compared to responding patients and HC, which was confirmed in patients with mesothelioma treated with CI therapy. CONCLUSIONS: These data show that the frequency of CD21- DN B cells correlates with lack of response to CI therapy in thoracic malignancies. The mechanism by which CD21- DN B cells hamper CI therapy remains unknown. Our findings support the hypothesis that CD21- DN B cells resemble phenotypically identical exhausted B cells that are seen in chronic infection or function as antigen presenting cells that induce regulatory T cells.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Belderbos RA, Corneth OBJ, Dumoulin D, et al. Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC. Eur J Cancer. 2023. PMID: 38039777. doi:10.1016/j.ejca.2023.113428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。